![]() ![]() Food and Drug Administration (FDA) approved reversal agent for patients treated with apixaban or rivaroxaban, as compared to 4F-PCC, which are highlighted as a second-in-line option for Factor Xa reversal and recommended for use only if Andexxa is not available. In the guidance statement, ACEP highlighted Andexxa ® as a first-in-line, U.S. The guidance statement is supported by literature and consensus definitions to support evaluation and treatment of the bleeding and nonbleeding patient requiring emergency invasive procedures. ® (NASDAQ: PTLA) today announced that Annals of Emergency Medicine, the journal of the American College of Emergency Physicians (ACEP), published a multidisciplinary anticoagulant reversal and replacement guidance statement. 15, 2019 /PRNewswire/ - Portola Pharmaceuticals, Inc.
0 Comments
Leave a Reply. |